Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
The Phase III trial included 1736 participants who demonstrated symptoms of the early stages of Alzheimer’s disease, in the form of amyloid plaques and tau pathology. The results of the trial, published in JAMA, showed that donanemab significantly slows the cognitive and functional decline in these patients.
"The positive TRAILBLAZER-ALZ 2 data bring hope to people with Alzheimer's disease who urgently need new treatment options. This is the first Phase III study of a disease-modifying therapy to replicate the positive clinical results observed in a previous study," explained Anne White, Executive Vice President of Eli Lilly and Company, and President of Lilly Neuroscience. "If approved, we believe donanemab can provide clinically meaningful benefits for people with this disease and the possibility of completing their course of treatment as early as 6 months once their amyloid plaque is cleared. We must continue to remove any barriers in access to amyloid-targeting therapies and diagnostics in an already complex healthcare ecosystem for Alzheimer's disease."
Previous announcements from Eli Lilly stated that donanemab had met all the primary and secondary endpoints laid out in the study, and based off of this, applied for US FDA approval to treat those with mild cognitive impairment or mild dementia, with approval applications to other global bodies currently in process.
In the 18-month trial, participants were split into groups according to their exhibited symptoms, a low/medium tau (68.1%) or high tau pathology (31.8%), which was determined using PET imaging from June 2020 to November 2021. Of those taking part initially, 1320 completed the trial.
The results showed that, out of the 24 outcomes measured and analysed, 23 were statistically significant and overall it was concluded that donanemab, when compared to placebo, slowed clinical progression in both groups of participants, at 76 weeks, according to the integrated Alzheimer's Disease Rating Scale (iADRS) and the Clinical Dementia Rating-Sum of Boxes (CDR-SB).
"These results demonstrate that diagnosing and treating people earlier in the course of Alzheimer's disease may lead to greater clinical benefit," added Liana Apostolova, a Professor in Alzheimer's disease research and Professor in neurology, radiology, medical and molecular genetics at Indiana University School of Medicine, where she is Associate Dean for Alzheimer's disease research and directs the clinical core of the Alzheimer's Disease Centre. "The delay of disease progression over the course of the trial is significant and will give people more time to do such things that are meaningful to them."
Donanemab is a monoclonal antibody that specifically singles out the deposits of amyloid plaque in the brain, and leads to clearance of the plaques. Without the plaques hindering normal brain function, patients can have a greater chance of living out a fuller life for longer.
The number of adverse events that occurred in patients throughout the trial were consistent with previous Alzheimer’s studies. This took the form of ARIA, which is expected with antibody-based therapies of this kind. The ARIAs can be detected via MRI scans, and treated as necessary.
"People living with early, symptomatic Alzheimer's disease are still working, enjoying trips, sharing quality time with family – they want to feel like themselves, for longer," commented Mark Mintun, Group Vice President of Neuroscience Research & Development at Lilly, and President of Avid Radiopharmaceuticals. "The results of this study reinforce the importance of diagnosing and treating disease sooner than we do today."
Source: Lilly. Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA. [Date accessed 18/07/2023]
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News Novo Nordisk announces expansion of Hillerød API manufacturing facility
Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance